Clinical Value of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Response Evaluation after Primary Treatment of Advanced Epithelial Ovarian Cancer

[1]  E. Trimble,et al.  Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Rockall,et al.  FDG PET/CT Pitfalls in Gynecologic and Genitourinary Oncologic Imaging. , 2017, Radiographics : a review publication of the Radiological Society of North America, Inc.

[3]  I. Vergote,et al.  Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. , 2016, Gynecologic oncology.

[4]  H. Jang,et al.  Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review , 2016, Oncotarget.

[5]  Martin A Lodge,et al.  Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. , 2016, Radiology.

[6]  Eric J. W. Visser,et al.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  Laura A. Gibson,et al.  Associations between Cancer-Related Information Seeking and Receiving PET Imaging for Routine Cancer Surveillance—An Analysis of Longitudinal Survey Data , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[8]  S. Grénman,et al.  A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer. , 2013, Gynecologic oncology.

[9]  M. Kohli,et al.  Response criteria in oncologic imaging: review of traditional and new criteria. , 2013, Radiographics : a review publication of the Radiological Society of North America, Inc.

[10]  John O. Prior,et al.  Reporting Guidance for Oncologic 18F-FDG PET/CT Imaging , 2013, The Journal of Nuclear Medicine.

[11]  Z. Keidar,et al.  FDG PET/CT in monitoring response to treatment in gynecological malignancies , 2013, Current opinion in obstetrics & gynecology.

[12]  R. Hruban,et al.  First report of the correlation of PET Response Criteria in Solid Tumors (PERCIST) criteria and pathologic change in patients with rectal cancer treated with neoadjuvant radiation. , 2013 .

[13]  V. Lowe,et al.  Oncologic 18F-FDG PET/CT: Referring Physicians’ Point of View , 2012, The Journal of Nuclear Medicine.

[14]  T. Watabe,et al.  Evaluation of Response to Neoadjuvant Chemotherapy for Esophageal Cancer: PET Response Criteria in Solid Tumors Versus Response Evaluation Criteria in Solid Tumors , 2012, The Journal of Nuclear Medicine.

[15]  M. Parmar,et al.  Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) , 2010, International Journal of Gynecologic Cancer.

[16]  G. Kenter,et al.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.

[17]  J. Ledermann,et al.  Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  A. Loft,et al.  Does the use of diagnostic PET/CT cause stage migration in patients with primary advanced ovarian cancer? , 2010, Gynecologic oncology.

[19]  Jae Hoon Kim,et al.  Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. , 2010, Gynecologic oncology.

[20]  Gang Huang,et al.  CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. , 2009, European journal of radiology.

[21]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[22]  Joel Karp,et al.  Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  Wolfgang A Weber,et al.  Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Burger,et al.  Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study. , 2005, Gynecologic oncology.

[25]  F. Fazio,et al.  Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. , 2004, Radiology.

[26]  Sungeun Kim,et al.  [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  L. Mortelmans,et al.  FDG-PET: procedure guidelines for tumour imaging , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[29]  D. Alberts,et al.  Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. , 1998, British Journal of Cancer.

[30]  Jacob Cohen,et al.  Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit. , 1968 .

[31]  S. Grénman,et al.  18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer. , 2016, Gynecologic oncology.

[32]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.